Citing documents OpenAI gave to investors, the Financial Times reported that the company's annualized revenue was close to $50 billion as of the end of September, far below the roughly $70 billion widely circulated in the market.
A team at LMU Munich has developed SPARCS, which uses AI to analyze microscope images of 70 million cells at once and systematically screen how gene changes affect cells, as reported in Cell on October 8, 2026.
In a statement on X on Friday, OpenAI confirmed it fired AI safety/alignment researchers Jasmine Wang, Tomek Korbak and Mikita Balesni last week, saying an internal investigation found they violated its sensitive-information policy. The three had publicly denied being the source of a leak.
Butterfly Effect, the parent company of Manus, has raised more than $500 million in a new round led by Boyu Capital and IDG Capital, with existing investors Tencent, Sequoia China and ZhenFund adding more, making it one of the largest AI agent financings this year.
From October 9, Google is restricting model access in Gemini: free users get only the weakest model, Flash-Lite, while the Flash and Pro models they could previously choose are withdrawn.
Anthropic says its Claude model helped discover a new enzyme system in bacteriophages, array-associated reverse transcriptases (ART), which feature CRISPR-like repeat arrays; 950 agents found it in 21 hours.
Illumina released SpliceAI2 on October 8, a genomic AI model that predicts how genetic variants alter RNA splicing, a key step in interpreting variants of uncertain significance.
XtalPi disclosed details of its Kodexia platform on October 6, in which generative AI, biological modeling and automated experiments form a closed loop to speed up the discovery of small interfering RNA (siRNA) therapies.
A New York University team reports in Chemical Science an AI trained to predict hydrogen atom positions in drug molecules from stability-related chemical patterns, tackling the long-standing problem of tautomer assignment.
AI drug discovery company Transcripta Bio and "AI chemistry foundry" Synfini report obtaining a validation-grade lead compound against the MSH3 gene in a matter of weeks, versus an industry benchmark of 12-18 months from hit to candidate nomination.